William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of Dianthus Therapeutics’ DNTH103 as a leading complement inhibitor in the treatment of rare autoimmune diseases. The company’s approach focuses on selective targeting of the classical pathway through active C1s inhibition, which is expected to offer a superior safety profile compared to existing treatments, as it poses less immunosuppressive risk. This strategic focus positions DNTH103 as a potentially best-in-class option, especially given its compatibility with autoinjectors.
Minter also points to upcoming catalysts that could drive the stock’s performance. The anticipated top-line data from the Phase II MaGic trial in generalized myasthenia gravis, expected in September 2025, could significantly impact the stock, especially in the competitive landscape shaped by recent approvals of FcRn antagonists. Furthermore, the interim data from the Phase II/III CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy, expected in the latter half of 2026, along with the MoMeNtum Phase II study in multifocal motor neuropathy, are seen as pivotal events that could validate the efficacy and safety of DNTH103, reinforcing its market potential.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $52.00 price target.